RATIONALE-302 evaluated outcomes with TEVIMBRA monotherapy vs chemotherapy in patients with unresectable or metastatic ESCC that had progressed during or after 1L systemic treatment1,2
This trial was a randomized, phase 3 study conducted globally in 11 countries across Asia, Europe, and North America
TEVIMBRA was tested across a broad range of patients with 2L ESCC
*There were 50 patients from Japan.
1L, first line; 2L, second line; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; ESCC, esophageal squamous cell carcinoma; IV, intravenous; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; PS, performance status; Q3W; every 3 weeks; QW, every week; R, randomization; RECIST, Response Evaluation Criteria in Solid Tumors.
References: 1. TEVIMBRA. Prescribing Information. San Mateo, CA: Beigene, Ltd.; 2025. 2. Shen L, Kato K, Kim S-B, et al; RATIONALE-302 Investigators. J Clin Oncol. 2022;40(26):3065-3076. doi:10.1200/JCO.21.01926